AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novel Coronavirus Treatment

907.953

-5.324-0.58%

Number of Gainers:9

Number of Losers:6

Number of Flat:17

PE:- -

High:915.545

Open:915.545

Low:907.698

Close:913.277

Volume:11.51M

Turnover:35.85M

Market Cap:235.89B

Float Cap:182.86B

Loading ...

Even With A 26% Surge, Cautious Investors Are Not Rewarding Genetic Signatures Limited's (ASX:GSS) Performance Completely

Simply Wall St.

Gold X2 Advances Environmental Studies for Moss Gold Project in Ontario

Workato Launches AI Lab in Singapore to Accelerate Applied AI Innovation and Talent Development

Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys

MT Newswires Live

September 'Painful' Month for Long-Term Quality Growth Investors, Says BofA

MT Newswires Live

Grassroots leagues revive China's soccer dream

Shareholders Will Likely Find Advance ZincTek Limited's (ASX:ANO) CEO Compensation Acceptable

Simply Wall St.

Genetic Signatures Updates CEO Remuneration

MT Newswires Live

Hamish Douglass bought it when no one would - now Bell Potter’s doing the same

Genetic Signatures Ltd-Chief Executive Officer Remuneration Update

THOMSON REUTERS

Haemonetics reports second quarter revenue of $327 million and earnings per diluted share of $0.81

WOW (WideOpenWest): Losses Worsen, Profitability Outlook Challenges Bull Case

Simply Wall St.

BUZZ-Australia's Zoono rises on packaging deal with South Africa's Mpact

Zoono Group Ltd - South African Packaging Agreement With Mpact

THOMSON REUTERS

BRIEF-CSL Ltd Sees High Single-Digit NPAT Growth Beyond FY26

CSL Ltd Sees Continued Dividends and Multi-Year, on-Market Share Buybacks Beyond FY26

THOMSON REUTERS

CSL Ltd Sees Mid Single-Digit Revenue Growth Beyond FY26

THOMSON REUTERS

Mesoblast To Meet With FDA Next Month To Discuss Rexlemestrocel-L And Opioid Cessation

Playing India... (not just at cricket)

Cynata Therapeutics Ltd-Cynata Receives $1.7M R&D Tax Incentive Refund

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7501/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"Novel Coronavirus Treatment","latestPrice":907.95306,"timestamp":1762731941752,"preClose":913.27673,"halted":0,"volume":11509562,"delay":0,"changeRate":-0.005829,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-5.323669,"latestTime":"11-10 10:45:42 AEDT","open":915.5452,"high":915.5452,"low":907.6975,"amount":35846732,"amplitude":0.008593,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1762750800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1762729200000,1762750800000]],"turnoverRate":0.000799,"increases":10,"decrements":8,"flats":14,"marketCap":235889688838.25,"floatMarketCap":182855788775.58594},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":915.5452,"amplitude":0.008593,"preClose":913.27673,"low":907.6975,"latestPrice":907.95306,"volume":11509562,"delay":0,"open":915.5452,"prevYearClose":1117.913,"prevWeekClose":913.277,"prevMonthClose":914.468,"prevQuarterClose":950.171,"fiveDayClose":902.484,"twentyDayClose":972.908,"sixtyDayClose":1133.772,"secType":"PLATE","market":"AU","turnoverRate":0.000799,"marketCap":235889688838.25,"floatMarketCap":182855788775.58594,"timestamp":1762731941752,"nameCN":"Novel Coronavirus Treatment"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":9,"down":6,"flat":17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582810893","title":"Even With A 26% Surge, Cautious Investors Are Not Rewarding Genetic Signatures Limited's (ASX:GSS) Performance Completely","url":"https://stock-news.laohu8.com/highlight/detail?id=2582810893","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582810893?lang=en_us&edition=fundamental","pubTime":"2025-11-09 06:32","pubTimestamp":1762641131,"startTime":"0","endTime":"0","summary":"Those holding Genetic Signatures Limited ( ASX:GSS ) shares would be relieved that the share price has rebounded 26% in...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-gss/genetic-signatures-shares/news/even-with-a-26-surge-cautious-investors-are-not-rewarding-ge","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-gss/genetic-signatures-shares/news/even-with-a-26-surge-cautious-investors-are-not-rewarding-ge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7048","BK4211","BK7501","ISBC","GSS.AU"],"gpt_icon":0},{"id":"2581022400","title":"Gold X2 Advances Environmental Studies for Moss Gold Project in Ontario","url":"https://stock-news.laohu8.com/highlight/detail?id=2581022400","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581022400?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:01","pubTimestamp":1762516913,"startTime":"0","endTime":"0","summary":"Gold X2 Mining Inc. has announced a significant update on the environmental baseline studies for its Moss Gold Project in Northwest Ontario, Canada. The studies, which began in 2021 and have expanded through 2025, are a key part of the company's strategy to de-risk the project from an environmental permitting perspective. Led by CSL Environmental & Geotechnical Ltd., the program emphasizes engagement with Indigenous Communities to ensure environmental and cultural considerations are integrated into project planning. Gold X2 expects to complete the baseline studies by the end of 2026 and plans to enter the formal permitting process with a feasibility study in 2027. The company aims to submit both Provincial and Federal Environmental Assessment applications in the third quarter of 2027, moving the project closer to regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL7yTP6k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7067","BK7508","BK7501","BK7511"],"gpt_icon":0},{"id":"2581807427","title":"Workato Launches AI Lab in Singapore to Accelerate Applied AI Innovation and Talent Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2581807427","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581807427?lang=en_us&edition=fundamental","pubTime":"2025-11-07 16:04","pubTimestamp":1762502640,"startTime":"0","endTime":"0","summary":"Supported by the Digital Industry Singapore , the AI Lab aims to advance Singapore's leadership in building an AI-enabled workforce for the future  SINGAPORE, Nov. 7, 2025 /PRNewswire/ --Workato, the leader in agentic orchestration, announced today the launch of the Workato AI Lab in Singapore, marking a major milestone in its commitment to nurturing AI talent and driving real-world innovation through industry-academia collaboration. A strategic initiative supported by the Digital Industry Singapore , the AI Lab underscores Workato's commitment to accelerating AI adoption for businesses both locally and across the region.","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2816704/Group_Shot.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2816704/Group_Shot.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/workato-launches-ai-lab-in-singapore-to-accelerate-applied-ai-innovation-and-talent-development-302608463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4587","BK7501","BK4551","BK7511","BK4023","AAQC","BK4528","AI","BK4543","WOW.AU","BK4100","BK4585","WOW","BK7040","BK4588"],"gpt_icon":0},{"id":"2581076953","title":"Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2581076953","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581076953?lang=en_us&edition=fundamental","pubTime":"2025-11-07 15:02","pubTimestamp":1762498924,"startTime":"0","endTime":"0","summary":"If Dimerix's  US peer Travere's drug Filspari is approved by the US Food and Drug Administration, it would likely be positive for Dimerix, but the consequences would be neutral if rejected, said Euroz Hartleys in a Friday note.The research firm believes that the Filspari launch would raise awareness of focal segmental glomerulosclerosis , improve diagnosis, and establish insurance support for rare kidney disease treatments, and as doctors are expected to use Dimirex's DMX-200 together with Filspari, it could help accelerate acceptance of the medication.If the US FDA rejects Filspari, the effect would likely be neutral for Dimerix, the note added.Euroz Hartleys said that Travere's setback would stem from its trial design, not the medical need. Dimerix's own placebo-controlled study with clear goals follows a stronger regulatory path, keeping its outlook intact.Euroz Hartleys has maintained its speculative buy rating on Dimerix with a price target of AU$1.68.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FSGS","BK7508","BK7067","BK7501","DXB.AU"],"gpt_icon":0},{"id":"2581279510","title":"September 'Painful' Month for Long-Term Quality Growth Investors, Says BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2581279510","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581279510?lang=en_us&edition=fundamental","pubTime":"2025-11-07 13:09","pubTimestamp":1762492193,"startTime":"0","endTime":"0","summary":"September was a \"painful\" month for long-term quality growth investors in Australia as the Steady Compounder stocks underperformed by around 5.4%, said Bank of America in a Friday report.The top-ranked stocks by the triple momentum method were Evolution Mining , Northern Star , Newmont , Life360 , and Zip , the report added.The bank said that so far this year, global funds have bought the most shares in Block, Sigma Healthcare , Goodman , Northern Star Resources, and Aristocrat , while selling Newmont, Amcor , Rio Tinto , and CSL .The bank noted that the main Australian share index rose by 0.4%, while global shares gained 2.2%.The materials sector led gains, with seven of the ten best-performing stocks coming from this sector. Meanwhile, the weakest momentum was seen in energy, utilities, and health care sectors, with Yancoal , CSL, Xero , and Fisher & Paykel Health  at the bottom.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FPH.AU","ZIP.AU","AMC.AU","ALL.AU","XJO.AU","RIO.AU","BK7509","BK7506","BK7103","GMG.AU","BK7093","YAL.AU","BK7007","BK7158","BK4211","CSL.AU","ISBC","XKO.AU","BK7155","XYZ.AU","BK7099","SIG.AU","XAO.AU","BK7104","BK7511","BK7067","NST.AU","BK7508","BK7016","BK7063","EVN.AU","BK7503","BK7501","BK7083","BK7510","XRO.AU","BK7507","BK7078","NEM.AU","360.AU","BK7095"],"gpt_icon":0},{"id":"2581702433","title":"Grassroots leagues revive China's soccer dream","url":"https://stock-news.laohu8.com/highlight/detail?id=2581702433","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581702433?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:00","pubTimestamp":1762488000,"startTime":"0","endTime":"0","summary":"Grassroots leagues revive China's soccer dreamChinese soccer historically plagued by poor performances, match fixing, corruptionAmateur leagues on the rise after success of rural games played by farmers, blue-collar workersAmateur talent helps to revive China's dream of becoming soccer superpowerBy Qiaoyi Li, Josh Arslan and Tingshu Wang","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL3N3VG0DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7511","BK7508","CSL.AU","BK7067"],"gpt_icon":0},{"id":"2581020753","title":"Shareholders Will Likely Find Advance ZincTek Limited's (ASX:ANO) CEO Compensation Acceptable","url":"https://stock-news.laohu8.com/highlight/detail?id=2581020753","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581020753?lang=en_us&edition=fundamental","pubTime":"2025-11-07 09:44","pubTimestamp":1762479866,"startTime":"0","endTime":"0","summary":"Key Insights Advance ZincTek to hold its Annual General Meeting on 14th of November Salary of AU$292.3k is part of CEO...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice1-main-header/1585186700183","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice1-main-header/1585186700183"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ano/advance-zinctek-shares/news/shareholders-will-likely-find-advance-zinctek-limiteds-asxan","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ano/advance-zinctek-shares/news/shareholders-will-likely-find-advance-zinctek-limiteds-asxan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ANO.AU","BK7501","BK7036"],"gpt_icon":0},{"id":"2581040241","title":"Genetic Signatures Updates CEO Remuneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2581040241","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581040241?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:51","pubTimestamp":1762476717,"startTime":"0","endTime":"0","summary":"Genetic Signatures  revised the remuneration package for Chief Executive Allison Rossiter, setting her base salary at AU$515,000 and introducing performance-based long-term incentives worth up to 25% of her salary, effective Oct. 1, according to a Friday filing with the Australian bourse.All other elements of her prior remuneration and termination arrangements remain unchanged, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7048","BK7501","GSS.AU"],"gpt_icon":0},{"id":"2581041396","title":"Hamish Douglass bought it when no one would - now Bell Potter’s doing the same","url":"https://stock-news.laohu8.com/highlight/detail?id=2581041396","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581041396?lang=en_us&edition=fundamental","pubTime":"2025-11-07 07:35","pubTimestamp":1762472103,"startTime":"0","endTime":"0","summary":"Back in 2015 at a grand adviser roadshow hosted by Magellan Financial Group, then-chief investment officer Hamish Douglass provided what everyone expected: a portfolio update filled with the usual suspects: Mastercard, Visa, Nestlé, Microsoft, Walmart…Then he revealed a name that confused even his most devout followers: Woolworths.I was the first one to ask the question: “Hamish, I thought you invest only in quality businesses?”Douglass, arguably in his prime as an active manager at the time, chuckled and explained that Australia had one of the most attractive grocery markets in the world in terms of margins, profitability and concentration of operators.At the time, Woolies’ share price had been smashed down from $31 to $18 amid what he called “the perfect storm of mismanagement.\" The company was pouring money into its loss-making Masters hardware chain  while ceding supermarket customers on price.The Magellan Global Fund became greedy when others were fearful back in 2015; Bell Potter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/hamish-douglass-bought-it-when-no-one-would-now-bell-potter-s-doing-the-same","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/hamish-douglass-bought-it-when-no-one-would-now-bell-potter-s-doing-the-same","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7040","XAO.AU","BK7082","COL.AU","XJO.AU","XKO.AU","WOW.AU","BK7511","BK7501"],"gpt_icon":0},{"id":"2581204587","title":"Genetic Signatures Ltd-Chief Executive Officer Remuneration Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581204587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581204587?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:41","pubTimestamp":1762465278,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUEC3MTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7048","GSS.AU"],"gpt_icon":0},{"id":"2581065005","title":"Haemonetics reports second quarter revenue of $327 million and earnings per diluted share of $0.81","url":"https://stock-news.laohu8.com/highlight/detail?id=2581065005","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581065005?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:01","pubTimestamp":1762426885,"startTime":"0","endTime":"0","summary":"Haemonetics Corporation reported second quarter fiscal 2026 revenue of $327 million, a decrease of 5.0 percent compared to the prior year period. Year-to-date revenue was $649 million, also down 5.0 percent. Organic revenue decreased by 1.8 percent in the quarter and 0.7 percent year-to-date. Excluding CSL, organic revenue increased by 9.4 percent in the quarter and 11.1 percent year-to-date. Earnings per diluted share were $0.81 for the quarter and $1.51 year-to-date. Adjusted earnings per diluted share were $1.27 for the quarter and $2.36 year-to-date. The company raised its total company fiscal 2026 guidance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6TM5md:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z6F94.USD","CSL.AU","LU1169589451.USD","IE00BLDYK493.USD","IE0034390439.USD","LU1169590202.USD","HAE","LU0205194284.USD","BK7508","LU0106261612.USD","BK4198","LU0205193047.USD","LU0012050646.USD","BK7511","BK7067","BK7501","IE00B64QTZ34.USD"],"gpt_icon":0},{"id":"2581395960","title":"WOW (WideOpenWest): Losses Worsen, Profitability Outlook Challenges Bull Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2581395960","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581395960?lang=en_us&edition=fundamental","pubTime":"2025-11-06 08:44","pubTimestamp":1762389842,"startTime":"0","endTime":"0","summary":"WideOpenWest (WOW) remains in the red, showing no recent progress in improving its profit margins. Over the last five years, losses have worsened at an annual rate of 12.7%. Consensus expects revenue to decline 2.8% per year over the next three years. With forecasts pointing to continued unprofitability, investors face a story of persistent losses and declining top-line numbers in the coming years.\nSee our full analysis for WideOpenWest.\nNext, we will compare these headline numbers with the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9612013-choice2-main-header/1585186865120","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9612013-choice2-main-header/1585186865120"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/media/nyse-wow/wideopenwest/news/wow-wideopenwest-losses-worsen-profitability-outlook-challen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/media/nyse-wow/wideopenwest/news/wow-wideopenwest-losses-worsen-profitability-outlook-challen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["WOW","BK7511","BK4100","BK7501","BK7040","WOW.AU"],"gpt_icon":0},{"id":"2581084813","title":"BUZZ-Australia's Zoono rises on packaging deal with South Africa's Mpact","url":"https://stock-news.laohu8.com/highlight/detail?id=2581084813","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581084813?lang=en_us&edition=fundamental","pubTime":"2025-11-06 08:28","pubTimestamp":1762388888,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Zoono riseson packaging deal with South Africa's Mpact** Shares of antimicrobial products manufacturer Zoono Group  ZNO.AX rise as much as 43.5% to A$0.066, their highest since May 21** Co and its partner OSY Group enter an exclusive agreement with South Africa-based Mpact Operations** Agreement allows Mpact to use ZNO's shelf-life extension products and OSY's application technologies to improve its own packaging solutions ** Says minimum purchases over the five-year term to maintain exclusivity will total NZ$5.1 million ** Trading volumes ~7x the 30-day average of 185,620 shares** Stock up 164% YTD, including the day's move","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL6N3WI00V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","ZNO.AU","BK7036"],"gpt_icon":0},{"id":"2581702182","title":"Zoono Group Ltd - South African Packaging Agreement With Mpact","url":"https://stock-news.laohu8.com/highlight/detail?id=2581702182","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581702182?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:27","pubTimestamp":1762378043,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WH2HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZNO.AU","BK7036","BK7501"],"gpt_icon":0},{"id":"2581749169","title":"BRIEF-CSL Ltd Sees High Single-Digit NPAT Growth Beyond FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2581749169","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581749169?lang=en_us&edition=fundamental","pubTime":"2025-11-05 16:27","pubTimestamp":1762331238,"startTime":"0","endTime":"0","summary":"BRIEF-CSL Ltd Sees High Single-Digit NPAT Growth Beyond FY26Nov 5  - CSL Ltd CSL.AX:SEES MID SINGLE-DIGIT REVENUE GROWTH BEYOND FY26SEES HIGH SINGLE-DIGIT NPAT GROWTH BEYOND FY26SEES CONTINUED DIVIDENDS AND MULTI-YEAR, ON-MARKET SHARE BUYBACKS BEYOND FY26Further company coverage: CSL.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WG24R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7511","CSL.AU","BK7067"],"gpt_icon":0},{"id":"2581749800","title":"CSL Ltd Sees Continued Dividends and Multi-Year,  on-Market Share Buybacks Beyond FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2581749800","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581749800?lang=en_us&edition=fundamental","pubTime":"2025-11-05 16:21","pubTimestamp":1762330867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WG24R:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7067","BK7511","CSL.AU"],"gpt_icon":0},{"id":"2581498077","title":"CSL Ltd Sees Mid Single-Digit Revenue Growth Beyond FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2581498077","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581498077?lang=en_us&edition=fundamental","pubTime":"2025-11-05 16:21","pubTimestamp":1762330867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WG24R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","BK7508","CSL.AU","BK7067"],"gpt_icon":0},{"id":"2581679772","title":"Mesoblast To Meet With FDA Next Month To Discuss Rexlemestrocel-L And Opioid Cessation","url":"https://stock-news.laohu8.com/highlight/detail?id=2581679772","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581679772?lang=en_us&edition=fundamental","pubTime":"2025-11-05 09:44","pubTimestamp":1762307064,"startTime":"0","endTime":"0","summary":"Nov 5 (Reuters) - Mesoblast Ltd ::*MESOBLAST TO MEET WITH FDA NEXT MONTH TO DISCUSS REXLEMESTROCEL-L AND OPIOID CESSATION*Further company coverage: MSB.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((Re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nRSD9dg7YS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MSB.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2581943577","title":"Playing India... (not just at cricket)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581943577","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581943577?lang=en_us&edition=fundamental","pubTime":"2025-11-05 09:23","pubTimestamp":1762305786,"startTime":"0","endTime":"0","summary":"As global investors shift their focus to resilient growth markets, India has become an attractive destination, and Australian companies are seizing the opportunity. From infrastructure and resources to telecom and healthcare, ASX-listed firms are steadily integrating themselves into India’s economic rise.Macquarie Group  has been a leader in infrastructure financing in India, supporting toll roads, renewable energy parks, and public-private partnerships. With India’s infrastructure spending expected to surpass USD $1.4 trillion by 2030, Macquarie’s significant investment in transport and energy assets positions it as a key player in the country’s growth story.BHP Group  continues to provide metallurgical coal and critical minerals to Indian steelmakers, while also exploring opportunities in copper and potash—key for India’s EV goals and agricultural needs. With India boosting domestic manufacturing and clean energy efforts, BHP’s resources align well with the country’s industrial prior","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/playing-india-not-just-at-cricket","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/playing-india-not-just-at-cricket","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["MQG.AU","BK7135","CSL.AU","BHP.AU","BK7507","BK7508","XJO.AU","BK7511","XKO.AU","TLS.AU","XAO.AU","BK7067","BK7501","BK7046","ANZ.AU","BK7095","BK7042"],"gpt_icon":0},{"id":"2581792930","title":"Cynata Therapeutics Ltd-Cynata Receives $1.7M R&D Tax Incentive Refund","url":"https://stock-news.laohu8.com/highlight/detail?id=2581792930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581792930?lang=en_us&edition=fundamental","pubTime":"2025-11-05 09:14","pubTimestamp":1762305248,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUE7KZHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYP.AU","BK7508","BK7501","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":109,"code":"91000000","status":"200"}]}}